300683 Stock Overview
A biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Wuhan Hiteck Biological Pharma Co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥28.50 |
| 52 Week High | CN¥50.89 |
| 52 Week Low | CN¥18.80 |
| Beta | -0.32 |
| 11 Month Change | 10.72% |
| 3 Month Change | 25.22% |
| 1 Year Change | -32.78% |
| 33 Year Change | -33.66% |
| 5 Year Change | -0.38% |
| Change since IPO | -39.91% |
Recent News & Updates
Shareholder Returns
| 300683 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 8.0% | -4.1% | -1.2% |
| 1Y | -32.8% | -16.9% | 3.1% |
Return vs Industry: 300683 underperformed the CN Biotechs industry which returned -16.2% over the past year.
Return vs Market: 300683 underperformed the CN Market which returned 5.7% over the past year.
Price Volatility
| 300683 volatility | |
|---|---|
| 300683 Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in CN Market | 12.0% |
| 10% least volatile stocks in CN Market | 5.3% |
Stable Share Price: 300683 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300683's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 1,520 | Ya Chen | www.hiteck.com.cn |
Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China. Its products includes Anewway, a mouse nerve growth factor for injection; omeprazole sodium for injection, an alternative therapy for duodenal ulcer, gastric ulcer, reflux esophagitis, and Zollinger-Ellison syndrome; adenosine cyclophosphate for injection that is used for angina pectoris, myocardial infarction, myocarditis, and cardiogenic shock; aciclovir dispersible tablets for the treatment of genital herpes virus infection, herpes zoster, and immune deficiency chickenpox; indometacin and furazolidone suppositories for internal and external hemorrhoids, anal swelling, fistula, and other anorectal diseases; tinidazole suppositories for trichomonas vaginitis and bacterial vaginosis; nimodipine sustained release tablets for ischemic cerebrovascular disease, migraine, and cerebral vasospasm; trimetazidine dihydrochloride tablets for treatment of stable angina; and azithromycin granules for treatment of acute pharyngitis, tonsillitis, and bronchitis. The company also provides measles and rubella virus nucleic acid detection kit; isolation and identification tube and kit for mycoplasma; and bacterial vaginosis (BV) rapid test kit, as well as diagnostic kit for novel coronavirus N-Protein.
Wuhan Hiteck Biological Pharma Co.,Ltd Fundamentals Summary
| 300683 fundamental statistics | |
|---|---|
| Market cap | CN¥3.73b |
| Earnings (TTM) | -CN¥134.13m |
| Revenue (TTM) | CN¥614.85m |
6.1x
P/S Ratio-27.8x
P/E RatioIs 300683 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300683 income statement (TTM) | |
|---|---|
| Revenue | CN¥614.85m |
| Cost of Revenue | CN¥371.97m |
| Gross Profit | CN¥242.88m |
| Other Expenses | CN¥377.01m |
| Earnings | -CN¥134.13m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.02 |
| Gross Margin | 39.50% |
| Net Profit Margin | -21.81% |
| Debt/Equity Ratio | 1.8% |
How did 300683 perform over the long term?
See historical performance and comparison